Long-Term Liabilities: The sum of all non-current liabilities.
SAB Biotherapeutics, Inc. (SABS) had Long-Term Liabilities of $7.58M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$5.34M |
|
-- |
|
-- |
|
$12.68M |
|
$-12.68M |
|
$58.12M |
|
$45.45M |
|
$45.45M |
|
$45.45M |
|
$45.45M |
|
$45.45M |
|
$45.45M |
|
$-12.68M |
|
$-11.94M |
|
10.66M |
|
77.86M |
|
$0.50 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$113.28M |
|
$13.11M |
|
$70.17M |
|
$183.45M |
|
$10.79M |
|
$3.16M |
|
|
Long-Term Liabilities |
$7.58M |
$18.37M |
|
$165.07M |
|
$165.07M |
|
$165.07M |
|
47.49M |
|
| Cash Flow Statement Financials | |
$-28.00M |
|
$-120.00M |
|
$168.34M |
|
$8.90M |
|
$29.42M |
|
$20.53M |
|
$2.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.50 |
|
-- |
|
-- |
|
0.02 |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-28.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
27.53% |
|
27.53% |
|
24.77% |
|
27.01% |
|
$3.48 |
|
$-0.36 |
|
$-0.36 |
|